%0 Journal Article %T Public Health Impact After the Introduction of PsA-TT: The First 4 Years %+ Centers for Disease Control and Prevention [Atlanta] (CDC) %+ World Health Organization Intercountry Support Team for West Africa %+ Centre de Support en Santé Internationale [N'Djamena, Tchad] (CSSI) %+ Norwegian Institute of Public Health [Oslo] (NIPH) %+ Centre de Recherche Médicale et Sanitaire (Niamey, Niger) (CERMES) %+ London School of Hygiene and Tropical Medicine (LSHTM) %+ WHO, Regional Office for Africa [Brazzaville, Republic of the Congo] %+ Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO) %+ PATH Europe [Ferney Voltaire] %+ Serum Institute of India Pvt. Ltd. [Pune, India] %A Diomandé, Fabien, V. K. %A Djingarey, Mamoudou, H. %A Daugla, Doumagoum, M. %A Novak, Ryan, T. %A Kristiansen, Paul, A. %A Collard, Jean-Marc %A Gamougam, Kadidja %A Kandolo, Denis %A Mbakuliyemo, Nehemie %A Mayer, Leonard %A Stuart, James %A Clark, Thomas %A Tevi-Benissan, Carol %A Perea, William, A. %A Preziosi, Marie-Pierre %A Marc Laforce, F. %A Caugant, Dominique %A Messonnier, Nancy %A Walker, Oladapo %A Greenwood, Brian %< avec comité de lecture %@ 1058-4838 %J Clinical Infectious Diseases %I Oxford University Press (OUP) %V 61 %N suppl_5 %P S467-S472 %8 2015-11-09 %D 2015 %R 10.1093/cid/civ499 %M 26553676 %K Africa meningitis belt %K PsA-TT %K disease incidence %K meningococcal group A %K vaccine evaluation framework %Z Life Sciences [q-bio]/Human health and pathology/Infectious diseases %Z Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology %Z Life Sciences [q-bio]/Santé publique et épidémiologieJournal articles %X Background. During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.Methods. The new vaccine effectiveness evaluation framework was established by the World Health Organization and partners. Meningitis case-based surveillance was strengthened in PsA-TT first-introducer countries, and several evaluation studies were conducted to estimate the vaccination coverage and to measure the impact of vaccine introduction on meningococcal carriage and disease incidence.Results. PsA-TT implementation achieved high vaccination coverage, and results from studies conducted showed significant decrease of disease incidence as well as significant reduction of oropharyngeal carriage of group A meningococci in vaccinated and unvaccinated individuals, demonstrating the vaccine's ability to generate herd protection and prevent group A epidemics.Conclusions. Lessons learned from this experience provide useful insights in how to guide and better prepare for future new vaccine introductions in resource-limited settings. %G English %2 https://riip.hal.science/pasteur-03238511/document %2 https://riip.hal.science/pasteur-03238511/file/civ499.pdf %L pasteur-03238511 %U https://riip.hal.science/pasteur-03238511 %~ RIIP %~ SANTE_PUB_INSERM %~ RIIP_CERMES